Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle

Comprehensive review of the Zagreb group''s preclinical BPC-157 research across striated muscle (gastrocnemius, quadriceps, diaphragm), smooth muscle (GI tract, blood vessels), and cardiac muscle injury models in rats. Injury models included direct transection, crush injury, ischaemia-reperfusion, pharmacological toxicity, and anastomosis. Endpoints included tensile strength, histological fibre organisation, angiographic vessel density, and functional recovery measures.

BPC-157 consistently accelerated muscle repair across all three muscle types. In striated muscle: faster fibre regeneration, improved tensile strength, and reduced fibrosis compared to saline controls. In smooth muscle (GI): improved anastomosis healing, reduced ulcer area, and normalised GI motility. In cardiac muscle: reduced infarct size, improved ejection fraction, and accelerated angiogenesis in ischaemia-reperfusion models. The primary mechanism identified was VEGF upregulation driving angiogenesis, complemented by nitric oxide (NO) pathway activation improving tissue perfusion and FAK-paxillin axis activation promoting fibroblast migration. BPC-157 was active via both intraperitoneal and oral routes in rodent models — an unusual property for a peptide.

All data are from rodent preclinical models; human clinical data for BPC-157 in musculoskeletal repair are limited to case reports and early-phase investigations. The Zagreb group is the primary source of BPC-157 research, creating potential publication bias concerns. Route-of-administration effects in humans (particularly oral bioavailability) require direct clinical investigation.

This paper provides the mechanistic foundation and preclinical efficacy evidence for BPC-157 in musculoskeletal recovery research. It is the primary reference for BPC-157''s multi-tissue repair profile and VEGF/NO mechanism, and should be read alongside tendon-specific studies from the same group.